Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICO-D: Neoadjuvant Tislelizumab and CapeOX in Colon Cancer
NCT05833672Phase 2Not yet recruiting
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in colon cancer. Planned start May 2023; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05833672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833672.